| 17.16 15.79 (1152.55%) | 07-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.6 | 1-year : | 24.06 |
| Resists | First : | 17.63 | Second : | 20.6 |
| Pivot price | 16.1 |
|||
| Supports | First : | 7.57  |
Second : | 1.36 |
| MAs | MA(5) : | 16.05 |
MA(20) : | 16.07 |
| MA(100) : | 15.23 |
MA(250) : | 17.77 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.5 |
D(3) : | 51.7 |
| RSI | RSI(14): 59.8 |
|||
| 52-week | High : | 23.28 | Low : | 1.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IKNA ] has closed below upper band by 12.5%. Bollinger Bands are 0% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.17 - 17.3 | 17.3 - 17.39 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 16.99 - 17.19 | 17.19 - 17.35 |
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Fri, 25 Jul 2025
ImageneBio, Inc. Announces Merger Completion with Ikena Oncology, Begins Trading on Nasdaq Under 'IMA' - Quiver Quantitative
Fri, 25 Jul 2025
Inmagene-Ikena $75M Merger Creates New Atopic Dermatitis Drug Powerhouse ImageneBio - Stock Titan
Thu, 24 Jul 2025
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio - Investing.com
Wed, 23 Jul 2025
Roche-Acquired Poseida CEO Takes Helm at Ikena-Inmagene Merger with $75M Funding - Stock Titan
Tue, 15 Jul 2025
Ikena Oncology Shareholders Green Light Inmagene Merger: What the 1-for-12 Split Means for Investors - Stock Titan
Tue, 15 Jul 2025
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 76.2 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | -7.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 28.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.4 % |
| Return on Equity (ttm) | -23.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.72 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -2.24 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -24.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|